Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$141.75 USD

141.75
681,591

+2.42 (1.74%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks News

Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut

Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.

    Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates

    Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.

      Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y

      Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.

        Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates

        Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.

          Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View

          Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.

            SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1

            Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.

              Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated

              Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.

                QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4

                QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.

                  IDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View

                  IDEXX Laboratories Inc. (IDXX) recorded fourth-quarter 2016 earnings per share (EPS) of 58 cents, up 21% year over year on a reported basis.

                    Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues

                    Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.

                      Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View

                      Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.

                        Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance

                        Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.

                          Zacks.com featured highlights: DNB Financial, NVE, Nova Measuring Instruments, Glaukos and County Bancorp

                          Zacks.com featured highlights: DNB Financial, NVE, Nova Measuring Instruments, Glaukos and County Bancorp

                            Edwards Lifesciences (EW) Beats on Earnings & Sales in Q4

                            Edwards Lifesciences Corp. (EW) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%.

                              CONMED (CNMD) Q4 Earnings Miss Estimates, Increase Y/Y

                              Headquartered in Utica, NY, leading medical technology player, CONMED Corporation (CNMD) reported fourth-quarter 2016 adjusted earnings of 54 cents per share, missing the Zacks Consensus Estimate by 2 cents.

                                Baxter International (BAX) Q4 Earnings Beat, Revenues Lag

                                Baxter International Inc. (BAX) reported fourth-quarter 2016 adjusted earnings of 57 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and were well above the year-ago figure of 43 cents.

                                  Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue

                                  Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.

                                    Align Technology (ALGN) Q4 Earnings and Revenues in Line

                                    Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.

                                      Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017

                                      Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.

                                        Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve

                                        Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.

                                          Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite

                                          Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.

                                            Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat

                                            Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.

                                              Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3

                                              Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.

                                                C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

                                                C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

                                                  Quality Systems (QSII) Beats on Earnings & Revenues in Q3

                                                  Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.